Correlation of Leucine-Rich-α-2-Glycoprotein- 1 (LRG-1) Level in Urine with Cervical Cancer Stage, Histology Type and Histology Grading

Abstract

Objective: To determine if the level of LRG-1 in urine correlates with cervical cancer stage, histology type and histology grading Method: This cross-sectional study using ELISA to test urinary LRG-1 of 59 cervical cancer patients. Data were analyzed using Kruskal-Wallis test. Results: From the total of 59 samples, LRG-1 in urine ranged from 0.48 ng/mL to 170.43 ng/mL, with median value 58.42 ng/mL. A median value of 21.42±52.29 ng/mL was found in the urine at early stage and 115.32±59.36 ng/mL at advanced stage. Most patients had cervical cancer at advanced stage (69.4%), squamous cell carcinoma (66.1%), and grade cannot be assessed (45.8%). Median LRG-1 levels were highest in squamous cell carcinoma (66.42±60.89 ng/mL) and poorly differentiated (127.74 ±54.13 ng/mL). LRG-1 levels were significantly correlated with cervical cancer stage (p-value=0.045) but not histological type (p-value=0.940) or histopathological grade (p-value=0.488). Conclusion: The more advanced the cervical cancer stage, the more elevated urinary LRG-1 levels. LRG-1 contributes to angiogenesis and antiapoptotic processes in cancer. Further studies are required to identify and evaluate LRG-1 in urine as an important biomarker for making clinical decisions and developing potential treatments.